All In Biotech

Drug Trial Radar · NCT00067561

Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy

A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 0.5 mg QD, 1 mg QD and 1 mg BID of Alosetron in Female Subjects With Severe Diarrhea-predominant IBS Who Have Failed Conventional Therapy

Last checked: Nov 19, 2026Latest source record: Apr 16, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 702 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

702

Actual

Start

Jun 2003

Primary completion

Jan 2005

Study completion Jan 2005

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 25, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and effectiveness of different doses of an investigational medication in women with severe diarrhea-predominant Irritable Bowel Syndrome (IBS) who have failed conventional therapy.

Conditions

  • Irritable Colon
  • Irritable Bowel Syndrome (IBS)

Interventions

  • AlosetronDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject self assessment of improvement between treatment groups using the IBS Global Improvement Scale; comparison of safety and tolerability between treatment groups with respect to adverse events & laboratory abnormalities.

Locations

178 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Calera, Alabama

  • GSK Investigational Site

    Tuscaloosa, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Garden Grove, California

  • GSK Investigational Site

    Lancaster, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Rancho Cucamonga, California

  • GSK Investigational Site

    Redlands, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Rafael, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Santa Ana, California

  • GSK Investigational Site

    Upland, California

  • GSK Investigational Site

    Vista, California

  • GSK Investigational Site

    Yuba City, California

  • GSK Investigational Site

    Boulder, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Englewood, Colorado

  • GSK Investigational Site

    Wheat Ridge, Colorado

  • GSK Investigational Site

    Manchester, Connecticut

  • GSK Investigational Site

    Boca Raton, Florida

  • GSK Investigational Site

    Boynton Beach, Florida

  • GSK Investigational Site

    Boynton Beach, Florida

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Fort Myers, Florida

  • GSK Investigational Site

    Hialeah, Florida

  • GSK Investigational Site

    Hollywood, Florida

  • GSK Investigational Site

    Lake Worth, Florida

  • GSK Investigational Site

    Longwood, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Miami, Florida

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.